Pfizer and Ginkgo Bioworks Join Forces for $331M RNA Drug Development Deal
TL;DR Summary
Pfizer and Ginkgo Bioworks have entered into an R&D deal to develop RNA drugs, focusing on three therapeutic programs. The deal includes potential milestone payments of up to $331 million, with an undisclosed upfront amount. This collaboration reflects the growing importance of therapeutics in Ginkgo's business.
- Exclusive: Pfizer, Ginkgo sign R&D deal worth up to $331M to develop RNA drugs Endpoints News
- Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer PR Newswire
- Pfizer hooks up with Ginkgo for $331M biobucks deal on unspecified targets FierceBiotech
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
57%
108 → 46 words
Want the full story? Read the original article
Read on Endpoints News